Clinical Trials

Breast Neoplasms

NCT06961331 2026-01-09

Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

86 enrolled

Breast Neoplasms

NCT02420509 2025-06-04

Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis

Terminated

2 enrolled

Tumor-Agnostic

Neoplasms

NCT04260269 2024-12-12

CardioSwitch

Enrolling by invitation

200 enrolled

Other solid neoplasm

Solid Tumor

NCT04679597 2024-10-17

Total Neoadjuvant Therapy Versus Standard Therapy of Locally Advanced Rectal Cancer With High Risk Factors for Failure

161 enrolled

Rectal Neoplasms

NCT06504875 2024-07-17

Application of PD-1 Monoclonal Antibody in Combination With IL-2 and CapeOX in Organ Preservation Therapy for Ultra-Low Localized Advanced Rectal Cancer

Not yet recruiting

23 enrolled

Rectal Neoplasms

NCT04350021 2024-01-17

METRO

40 enrolled

Breast Cancer Metastatic

NCT06194981 2024-01-12

Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

260 enrolled

Stomach Neoplasms

NCT06169202 2023-12-13

A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients

50 enrolled

Fruquintinib

NCT03451370 2023-11-29

COBRA

121 enrolled

Elderly Metastatic Colorectal Cancer Patients

NCT05338866 2023-11-22

Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator

Enrolling by invitation

58 enrolled

Rectal Neoplasms

NCT06068023 2023-10-05

ADAPTA

Recruiting

400 enrolled

Ampullary Adenocarcinoma

NCT05176964 2023-09-25

Chemotherapy and Tislelizumab With Split-course HFRT for Locally Advanced Rectal Cancer

50 enrolled

Rectal Neoplasms

NCT06035016 2023-09-13

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

Recruiting

Breast Neoplasms

NCT04856761 2022-08-18

A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

160 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Cholangiocarcinoma

NCT05368051 2022-05-10

Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer

30 enrolled

Colorectal Neoplasms

NCT05131893 2021-11-23

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting

Breast Neoplasms

NCT02860234 2021-07-23

Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment

68 enrolled

Rectal Neoplasms

NCT04405206 2020-10-14

BJCC-R01

54 enrolled

Rectal Neoplasms

NCT04258163 2020-02-10

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

760 enrolled

Breast Neoplasms

NCT04132713 2019-10-21

Study on Skin Microbiome of HFS

50 enrolled

Microbiota

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Breast Cancer Organoids

NCT03923036 2019-04-22

AVOCETTE

2,000 enrolled

Colorectal Cancer Metastatic

NCT01310985 2019-03-01

A Trial of Pre-Operative Chemoradiotherapy Using Capecitabine, Radiation & Cetuximab, in Rectal Cancer

15 enrolled

Rectal Neoplasms

NCT02002195 2019-02-27

MATURE

47 enrolled

Stomach Neoplasms

NCT03532711 2018-05-22

Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer

264 enrolled

Colorectal Neoplasms

NCT01506167 2018-05-14

An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)

719 enrolled

Colorectal Neoplasms

NCT02479217 2017-02-17

Safety of Xeloda in Solid Tumours

1,268 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

NCT03015168 2017-01-09

Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients

117 enrolled

Rectal Neoplasms

NCT02656589 2016-10-13

microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin

Breast Neoplasms

NCT01399190 2016-09-28

An Observational Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) And Oxaliplatin in Patients With Colorectal Cancer

68 enrolled 8 charts

Colorectal Neoplasms

NCT01725386 2016-09-28

XEPAD

274 enrolled 11 charts

Breast Neoplasms

NCT01777945 2016-08-19

XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

46 enrolled 13 charts

Breast Neoplasms

NCT01442155 2016-07-07

An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer

74 enrolled 7 charts

Colorectal Neoplasms

NCT01664494 2016-05-02

An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer

563 enrolled 6 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT00235235 2015-12-09

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated

80 enrolled

Breast Neoplasms

NCT01782651 2015-08-10

Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients

1 enrolled

Breast Neoplasms

NCT01311050 2011-12-13

A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer

46 enrolled